HCG Education
HCG in Post-Cycle Therapy: How It Works, When to Use It, and What the Research Shows
Post-cycle therapy (PCT) is the protocol used after an anabolic steroid cycle to restore the body’s natural testosterone production. Human chorionic gonadotropin (HCG) is one of the most important compounds in this process because it directly stimulates the testes to produce testosterone at a time when the pituitary gland is unable to. Products like GENX-HCG, available through GenXtropin UK, are designed specifically for this purpose. This guide explains exactly how HCG fits into PCT, what the clinical research says about dosing and timing, and the critical concept of Leydig cell desensitization that determines whether HCG helps or hinders your recovery.
What Happens to the HPG Axis During a Steroid Cycle
The hypothalamic-pituitary-gonadal (HPG) axis is the hormonal feedback loop that controls testosterone production. The hypothalamus releases gonadotropin-releasing hormone (GnRH), which signals the anterior pituitary to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH then travels to the testes and stimulates the Leydig cells to produce testosterone. When testosterone levels are adequate, the hypothalamus and pituitary detect this through negative feedback and reduce GnRH and LH output accordingly.
When exogenous anabolic steroids are introduced, the body detects supraphysiological hormone levels and shuts down its own production. GnRH output drops. LH and FSH fall to near zero. Without LH stimulation, the Leydig cells stop producing testosterone and begin to atrophy. The longer the cycle runs and the higher the doses used, the more severe the suppression becomes. A review in Fertility and Sterility described this condition as anabolic steroid-induced hypogonadism (ASIH) and noted that the degree of suppression depends on dose, duration, and type of steroids used.
A scoping review published in Endocrine Connections found that near complete biochemical recovery of testosterone typically occurs over several months, with full gonadotropin recovery expected within 3 to 6 months. However, the review also identified that spontaneous recovery can take up to 24 months in some cases. A study published in Problems of Endocrinology tracking 44 former AAS users found that after 3 months of cessation and PCT, 20.5% of subjects still showed poor recovery, with clear negative correlations between recovery outcomes and the duration, quantity, and dose of steroids used.
Why HCG is Used During PCT
The core problem during the post-cycle window is that the pituitary gland is not yet sending LH to the testes. Without LH, the Leydig cells have no instruction to produce testosterone, and the user experiences hypogonadal symptoms: loss of muscle mass and strength, increased body fat, fatigue, impaired libido, mood changes, and in some cases depression.
HCG solves this by bypassing the suppressed pituitary entirely. It binds directly to the LH/CG receptor (LHCGR) on the Leydig cells and triggers the same intracellular signalling cascade that endogenous LH would, stimulating testosterone synthesis through the cAMP/PKA pathway and upregulation of StAR protein. This means the testes can begin producing testosterone again even while the pituitary is still recovering its ability to release LH naturally.
There is a critical distinction between what HCG does and what selective estrogen receptor modulators (SERMs) like clomiphene citrate (Clomid) and tamoxifen (Nolvadex) do. SERMs work at the hypothalamic and pituitary level by blocking estrogen’s negative feedback, which allows GnRH and LH production to resume. HCG works at the testicular level by directly stimulating the Leydig cells. The two approaches are complementary, not interchangeable. HCG restores testicular function from the bottom up. SERMs restore pituitary signalling from the top down. Most effective PCT protocols use both.
The Leydig Cell Desensitization Problem
Leydig cell desensitization is the single most important concept to understand when using HCG. If HCG is administered at excessive doses or for too long without interruption, the Leydig cells become less responsive to gonadotropin stimulation rather than more responsive. This is counterproductive during PCT because it makes the testes harder to reactivate, which is the opposite of the goal.
Research published in the Journal of Biological Chemistry demonstrated that sustained high-dose HCG exposure causes a loss of gonadotropin receptors on the cell surface and a decreased capacity for steroidogenesis. In rat models documented in Molecular and Cellular Endocrinology, a single high-dose HCG injection resulted in a 97% reduction in the steroidogenic enzyme CYP17 (cytochrome P450c17), although testosterone production only fell by 62% due to compensatory mechanisms within the cell. These findings show that the Leydig cells physically downregulate their receptor density and enzymatic capacity in response to overstimulation.
The practical implication is clear: moderate doses for a limited duration are effective. Excessive doses for prolonged periods are counterproductive. This is why HCG is typically used during the first phase of PCT (or on-cycle) and then discontinued before SERMs take over the recovery process.
What the Clinical Research Shows About HCG Dosing
Several clinical studies provide data on HCG dosing and its effects on testosterone production. Here are the most relevant findings for PCT applications.
Intratesticular Testosterone Preservation During Exogenous Testosterone Use
A study administering supraphysiological testosterone to healthy men found that intratesticular testosterone dropped by 94% in the placebo group. In men receiving concurrent low-dose HCG, the suppression was significantly attenuated: the 125 IU group saw a 25% reduction, the 250 IU group a 7% reduction, and the 500 IU group actually saw intratesticular testosterone increase by 26% above baseline, as reported in the Journal of Clinical Endocrinology and Metabolism. This demonstrates that even very low doses of HCG can maintain Leydig cell function during exogenous hormone use.
Randomised Trial: HCG vs Clomiphene vs Combination for Hypogonadism
A randomised study of 282 hypogonadal men compared three treatment arms: clomiphene citrate 50 mg daily, HCG 5,000 IU twice weekly, and a combination of both. All three groups achieved restoration of testosterone levels to the normal range. However, the combination group showed significantly greater improvement in symptom scores (qADAM) at both 1 month and 3 months compared to either agent alone, according to a randomised study published in BJU International. This supports the principle that HCG and SERMs work through different mechanisms and produce additive benefits when combined.
HCG for Anabolic Steroid-Induced Hypogonadism Recovery
A review published in Translational Andrology and Urology recommended initiating treatment with HCG 2,000 IU every other day alongside clomiphene citrate 50 mg every other day for recovery of spermatogenesis and testosterone production in men with AAS-induced hypogonadism. The review emphasised that HCG’s role in maintaining intratesticular testosterone is critical for preserving fertility, which exogenous testosterone alone cannot do.
On-Cycle HCG vs PCT-Only HCG: Which Approach Works Better
There are two schools of thought on when to introduce HCG, and the clinical data increasingly supports the preventive approach.
On-Cycle HCG (Preventive)
HCG is administered throughout the steroid cycle at 250 to 500 IU two to three times per week. The Leydig cells remain active and responsive throughout. Testicular volume is preserved. When the cycle ends and PCT begins, the testes are already functional and responsive to both HCG and the endogenous LH that SERMs help restore. Recovery is faster and smoother because there is no atrophied tissue to reawaken. The intratesticular testosterone preservation study in JCEM directly supports this approach.
PCT-Only HCG (Reactive)
HCG is introduced only after the steroid cycle has ended, during the PCT window. By this point the Leydig cells have been without stimulation for the entire cycle duration and have undergone varying degrees of atrophy. They need to be reactivated before they can produce testosterone at meaningful levels. This adds time and complexity to the recovery process. Higher doses are often used in this scenario (1,000 to 2,500 IU every other day for 2 to 3 weeks), which increases the risk of Leydig cell desensitization and estrogen elevation.
HCG and Estrogen: Managing the Aromatase Effect
HCG stimulates aromatase activity within the Leydig cells, which converts a portion of the testosterone produced into estradiol (an estrogen). This is a natural physiological response to gonadotropin stimulation, not a side effect of low quality HCG. At moderate on-cycle doses (250 to 500 IU), the estrogen increase is usually manageable. At the higher doses sometimes used during PCT-only protocols (1,000 to 2,500 IU), the estrogen increase can become significant enough to cause water retention, mood changes, or gynecomastia.
This is another reason why on-cycle HCG at lower doses is generally preferred. The estrogen management burden is lighter, and the risk of needing an aromatase inhibitor (AI) alongside the HCG is lower. If HCG is used during PCT at higher doses, monitoring estrogen symptoms and having an AI available is prudent.
Where HCG Fits in a Complete PCT Protocol
HCG is typically used during the first phase of PCT or throughout the preceding steroid cycle, and then discontinued before the SERM phase begins. The reasoning is that HCG itself suppresses LH release from the pituitary through negative feedback (just as exogenous testosterone does). If HCG is run concurrently with SERMs for an extended period, the HCG can partially counteract the SERMs’ goal of restoring endogenous LH production.
A common PCT timeline looks like this:
GENX-HCG is supplied as lyophilised powder that must be reconstituted with bacteriostatic water before injection. It is available through GenXtropin UK alongside GenXtropin HGH and GENX-MT2.
HCG PCT FAQ
What happens if I use too much HCG during PCT?
+
Excessive HCG doses or prolonged use causes Leydig cell desensitization. The cells downregulate their LH/CG receptors and reduce their steroidogenic enzyme capacity, making them less responsive to both HCG and the endogenous LH your pituitary produces once it recovers, as demonstrated in research published in the Journal of Biological Chemistry. This is counterproductive because it makes testosterone recovery harder, not easier. Elevated estrogen from increased aromatase activity is also a concern at high doses. Moderate doses for a limited duration avoid these problems.
Can I use HCG alone for PCT without a SERM?
+
HCG alone can restore testosterone production, but it does not address the root cause of post-cycle suppression, which is the shutdown of the hypothalamic-pituitary signalling that produces LH. HCG bypasses the pituitary, so while testosterone levels rise, the HPG axis itself is not being restimulated. Once HCG is stopped, testosterone will fall again unless the pituitary has recovered its LH output. SERMs like clomiphene and tamoxifen work at the pituitary level to restart endogenous LH production. A randomised study of 282 men published in BJU International showed that the combination of HCG and clomiphene produced significantly better symptom improvement than either agent alone.
How long does full testosterone recovery take after a steroid cycle?
+
It varies significantly based on the duration, dose, and type of steroids used. A scoping review in Endocrine Connections found that near complete testosterone recovery typically occurs over several months, with full gonadotropin recovery expected within 3 to 6 months. However, spontaneous recovery without PCT can take up to 24 months, and a study in Problems of Endocrinology found that 20.5% of former AAS users showed poor recovery even after 3 months of PCT. Using HCG on-cycle to maintain Leydig cell function throughout the cycle shortens the recovery window significantly because the testes are already active when PCT begins.
Can I use HCG alongside HGH during PCT?
+
Yes. HCG and somatropin (the active substance in GenXtropin HGH) work through entirely separate pathways. HCG stimulates the LHCG receptor on Leydig cells to produce testosterone. Somatropin binds to growth hormone receptors and stimulates IGF-1 production. The two do not interfere with each other and are commonly used together. Many users continue HGH through PCT and beyond because it supports body composition, recovery, and connective tissue health during the vulnerable post-cycle period.
Ready for PCT?
GENX-HCG is available from the official GenXtropin UK store alongside GenXtropin HGH 100IU and GENX-MT2. All orders ship with Royal Mail tracking and discreet packaging. Visit the reviews page to read customer feedback.
View GENX-HCGReferences
- Rahnema, C.D., Lipshultz, L.I., Crosnoe, L.E., Kovac, J.R., Kim, E.D. “Anabolic steroid-induced hypogonadism: diagnosis and treatment.” Fertility and Sterility, 2014; 101(5):1271-1279
- Smit, D.L., de Ronde, W. “Physical, psychological and biochemical recovery from anabolic steroid-induced hypogonadism: a scoping review.” Endocrine Connections, 2023
- Bondarenko, N.I. et al. “Peculiarity of recovery of the hypothalamic-pituitary-gonadal axis in men after using androgenic anabolic steroids.” Problems of Endocrinology, 2020; 66(1):104-112
- Lee, J.A., Ramasamy, R. “Indications for the use of human chorionic gonadotropic hormone for the management of infertility in hypogonadal men.” Translational Andrology and Urology, 2018; 7(Suppl 3):S348-S352
- Rebois, R.V., Bhatt, R.S. “Desensitization to gonadotropins in cultured Leydig tumor cells involves loss of gonadotropin receptors and decreased capacity for steroidogenesis.” Journal of Biological Chemistry, 1987
- Syed, V., Khan, S.A., Ritzen, E.M. “Stage-specific inhibition of interstitial cell testosterone secretion by rat seminiferous tubules in vitro.” Molecular and Cellular Endocrinology, 1997
- Coviello, A.D., Matsumoto, A.M., Bremner, W.J. et al. “Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression.” Journal of Clinical Endocrinology and Metabolism, 2005
- Helo, S., Mahon, J., Ellen, J. et al. “Clomiphene citrate and human chorionic gonadotropin are both effective in restoring testosterone in hypogonadism: a short-course randomized study.” BJU International, 2018